• Japanese
  • Korean
  • Chinese
Cover Image

Global Hyperphosphatemia Drugs Market 2015-2019

About hyperphosphatemia

Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.

Technavio's report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma

Other Prominent Vendors

  • Alkem
  • Amgen
  • Ardelyx
  • AstraZeneca
  • Baxter
  • Bayer
  • Chugai Pharmaceutical
  • Japan Tobacco
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Mylan
  • Natco
  • Novartis
  • Opko Health
  • Panion & BF Biotech
  • Roxane Laboratories
  • Sandoz
  • Synthon
  • Torri Pharmaceutical

Market driver

  • Increased number of people undergoing dialysis
  • For a full, detailed list, view our report

Market challenge

  • Non-adherence to treatment regimens
  • For a full, detailed list, view our report

Market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Product profiles

PART 05: Introduction

  • Key market highlights

PART 06: Disease Overview

  • Understanding the disease
  • Etiology
  • Effects of hyperphosphatemia
  • Causes
  • Signs and symptoms
  • Diagnosis
  • Management
  • Epidemiology

PART 07: Key developments in hyperphosphatemia therapy

PART 08: Guidelines for use of phosphate binders

  • CKD stages 2-4
  • CKD stage 5

PART 09: Pipeline analysis

  • Information on pipeline candidates

PART 10: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 11: Hyperphosphatemia management market dynamics

PART 12: Market segmentation by dosage form

  • Solid
  • Liquid

PART 13: Market segmentation by formulation

  • Aluminum-based phosphate binders
  • Calcium-based phosphate binders
  • Aluminum-free, calcium-free phosphate binder
  • Magnesium-based phosphate binders
  • Iron-based phosphate binders

PART 14: Geographical segmentation

  • Global hyperphosphatemia drugs market segmentation by geography
  • Hyperphosphatemia drugs market in Americas
  • Hyperphosphatemia drugs market in EMEA
  • Hyperphosphatemia drugs market in APAC

PART 15: Key leading countries

  • Key leading countries
  • Hyperphosphatemia drugs market in the US
  • Hyperphosphatemia drugs market in Japan

PART 16: Market drivers

PART 17: Impact of drivers

PART 18: Market challenges

PART 19: Impact of drivers and challenges

PART 20: Market trends

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Brand differentiation
  • Other prominent vendors

PART 22: Key vendor analysis

  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma

PART 23: Appendix

  • List of abbreviation

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Pathophysiology of hyperphosphatemia
  • Exhibit 03: Effects of hyperphosphatemia
  • Exhibit 04: Differential diagnosis of hyperphosphatemia
  • Exhibit 05: Ideal characteristics of phosphate binders
  • Exhibit 06: Advantages and disadvantages of different phosphate binders
  • Exhibit 07: Prevalence of CKD among participants by CKD stage in US 1988-2012
  • Exhibit 08: Number of dialysis patients worldwide 2012-2014 (millions)
  • Exhibit 09: Pipeline portfolio of hyperphosphatemia drugs
  • Exhibit 10: Global hyperphosphatemia drugs market 2014-2019 ($ millions)
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Market dynamics of phosphate binders for hyperphosphatemia
  • Exhibit 13: Segmentation of global hyperphosphatemia drugs market by dosage form
  • Exhibit 14: Segmentation of global hyperphosphatemia drugs market by formulation
  • Exhibit 15: Global hyperphosphatemia drugs market segmentation by geography 2014
  • Exhibit 16: Global hyperphosphatemia drugs market segmentation by geography 2014-2019 ($ millions)
  • Exhibit 17: Hyperphosphatemia drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 18: Hyperphosphatemia drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 19: Hyperphosphatemia drugs market in APAC 2014-2019 ($ millions)
  • Exhibit 20: Hyperphosphatemia drugs market in the US 2014-2019 ($ millions)
  • Exhibit 21: Hyperphosphatemia drugs market in Japan 2014-2019 ($ millions)
  • Exhibit 22: Number of individuals who underwent dialysis by region 2012-2014
  • Exhibit 23: Percentage of individuals who underwent dialysis by region 2012-2014
  • Exhibit 24: Global prevalence of diabetes 2014 and 2035 (millions)
  • Exhibit 25: Worldwide population aged 80 and above 1950-2050 (millions)
  • Exhibit 26: Impact of drivers
  • Exhibit 27: Rate of adherence to phosphate binders
  • Exhibit 28: Impact of drivers and challenges
  • Exhibit 29: R&D expenses by Auryxia 2012-2014 ($)
  • Exhibit 30: Global hyperphosphatemia market share analysis 2014
  • Exhibit 31: Ranking of vendors in market
  • Exhibit 32: Sanofi: YoY growth and revenue of Renagel and Renvela 2011-2014 ($ millions)
  • Exhibit 33: Sanofi: Revenue of Renagel and Renvela by region 2011-2014 ($ millions)
  • Exhibit 34: FOSRENOL: YoY growth and revenue of FOSRENOL except Japan 2011-2014 ($ millions)
  • Exhibit 35: Brand differentiation of phosphate binders by major vendors
  • Exhibit 36: Fresenius: Business segmentation by revenue 2014
  • Exhibit 37: Fresenius: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 38: Fresenius: Geographical segmentation by revenue 2014
  • Exhibit 39: Sanofi: Business segmentation 2014
  • Exhibit 40: Sanofi: Business segmentation by revenue 2014
  • Exhibit 41: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 42: Sanofi: Geographical segmentation by revenue 2014
  • Exhibit 43: Shire: Product segmentation by revenue 2014
  • Exhibit 44: Shire: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 45: Shire: Geographical segmentation by revenue 2014
  • Exhibit 46: Vifor Pharma: Product segmentation
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top